Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Medical Advisory Board
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
    • Video Resources
    • SSF Ambassador Program
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.



    Black Flag Racing

    Callan Spence: Survivor. Driver. Relentless Advocate.

    April 16, 2025 joshs Comments Off on Callan Spence: Survivor. Driver. Relentless Advocate.
    A smiling race car driver stands on a racetrack at Super Lap Battle 2025, holding a bottle and a blue award banner with "2025" and a "2" on it. FASTx Autosport cars and a scoreboard are visible in the background under a clear sky.

    Callan Spence isn’t waiting for progress—he’s chasing it down at full speed.

    At 20 years old, Callan is already a two-time synovial sarcoma fighter. But to see him now—helmet on, strapping into a 1,000-horsepower Lotus Exige—you’d never guess that this young man was once told he might not survive high school.

    In 2021, at just 16, Callan was diagnosed with synovial sarcoma. His tumor was massive and dangerously close to his spine. Doctors initially told his family the cancer was inoperable and advised them to consider palliative care. Callan and his family refused to accept that course. They pushed for advanced care and found it at Children’s Hospital of Philadelphia, where a team of six surgeons performed a 10-hour operation following rounds of chemotherapy and proton radiation.

    After a long and difficult recovery, Callan was declared NED—no evidence of disease—in October 2022.

    He and his family soon founded Black Flag Sarcoma Racing, a grassroots motorsports team built not just for speed, but for visibility. Their mission: to give synovial sarcoma a louder voice, create urgency for better treatments, and to turn passion into impact.

    “Callan represents everything this foundation stands for,” said Nathan Imperiale, Chairman of the Board for the Synovial Sarcoma Foundation. “He’s pushing the science forward, building a louder voice for patients, and living life boldly while doing it.”

    Callan is currently undergoing treatment for a recurrence of synovial sarcoma. And still—he races.

    At this year’s Super Lap Battle 2025 at Circuit of The Americas, Callan delivered a headline-making performance. He broke a class record and finished second overall in his division—an extraordinary accomplishment, especially while undergoing active treatment. 

    During the weekend, the Black Flag Sarcoma Racing pit area transformed into something much more than a garage. It became a hub of community and connection. Hundreds of families stopped by to meet Callan, share stories, and—for the youngest visitors—experience the thrill of sitting in his race car. The excitement, joy, and solidarity were undeniable.

    Also present was Joey Toro, a fellow synovial sarcoma patient, advocate, and active member of the Foundation’s community. Joey joined Callan at the track to show support and represent the powerful network of patients and families that continues to grow around this cause.The Black Flag car itself, developed with FASTx Autosport, prominently features the molecular structure of TumorGlow—a fluorescent imaging technology developed by Dr. Sunil Singhal at Penn Medicine that helps surgeons identify and remove cancerous tissue using near-infrared light. A key component of that technology is indocyanine green (ICG), a fluorescent dye produced by Diagnostic Green and already widely used in other surgical applications. What’s never been done—until now—is to study its potential in children and young adults with sarcoma.

    Through the Synovial Sarcoma Foundation—born out of the Spence Family Fund—Callan and his family are helping launch a groundbreaking clinical trial at CHOP to test TumorGlow specifically for sarcoma. The goal is clear: give surgeons better tools, and give patients better outcomes.

    Black Flag Sarcoma Racing is more than a team—it’s a movement. And Callan is more than a driver—he’s living proof that advocacy, community, and scientific momentum can go hand in hand, even in the face of a rare and relentless disease.

    Follow his journey on instagram: @blackflagsarcomaracing

    • Black Flag Racing
    • Callan Spence
    • Chas Spence
    • Rare Cancer
    • Synovial Sarcoma Foundation
    joshs

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Case Study (5)
    • Children (1)
    • CHOP (3)
    • Clinical Trial (4)
    • Development (12)
    • Dr. Theodore Laetsch (3)
    • Education (27)
    • Europe Expansion (1)
    • Healthcare (13)
    • Latest News (22)
    • Patient Story (1)
    • Programs (1)
    • Rare Cancer (7)
    • Rare Cancer Funding (2)
    • Research (21)
    • SSF Ambassador Program (1)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (7)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A doctor in a white coat with a stethoscope around their neck holds a tablet device, standing in a medical setting with a patient lying on a bed in the background.
      Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage
    • A scientist wearing blue gloves adjusts a microscope slide.
      Can We Reactivate T Cells After TCR-T Therapy Stops Working?
    • Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
      Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    Tags

    #AYACancer #CancerResearch #CaseReport #CellTherapy #ClinicalTrials #Immunotherapy #KnowYourOptions #MAGEA4 #MolecularDiagnostics #NYESO1 #PatientAdvocacy #RareCancer #RareDisease #Sarcoma #SarcomaAwareness #SoftTissueSarcoma #SS18SSX #SynovialSarcoma #SynovialSarcomaFoundation #TumorBoard Afami-cel Afamitresgene autoleucel Cancer Research CHOP immunotherapy MAGE-A4 synovial sarcoma NY-ESO-1 synovial sarcoma precision medicine Rare Cancer rare cancer research rare soft tissue sarcoma research sarcoma research sarcoma treatment soft tissue sarcoma Synovial Sarcoma synovial sarcoma biomarker testing synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma immunotherapy synovial sarcoma treatment T-Cell Therapy targeted therapy TCR Therapy TECELRA

    Related posts

    A scientist wearing blue gloves adjusts a microscope slide.
    Clinical Trial, Development

    Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    November 3, 2026 ayushis Comments Off on Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    A new pilot trial at Northwestern University is asking one of the most important questions in synovial sarcoma treatment: when TCR-T therapy stops working, are the T cells truly gone, or can they be brought back to life? Background: The Promise and the Limit of TCR-T Therapy TCR-T cell therapy represents a major advance for […]

    Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
    Latest News, Synovial Sarcoma Registry

    Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    October 28, 2026 ayushis Comments Off on Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    A new study in Advanced Science (October 12, 2026) shows what becomes possible when patients donate tumor tissue and researchers pair it with detailed clinical and genetic data. The same idea drives the Synovial Sarcoma Registry and Biorepository, and every patient who joins makes the next study possible. What the study found Over ten years, […]

    Close-up of blue gloved hands adjusting a microscope with two visible objective lenses, focusing on a glass slide in a laboratory setting.
    Education, Research

    The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    September 14, 2026 ayushis Comments Off on The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    A new study published in PLOS One by Ji-Yong Sung, Jin-Hong Kim, and Yi-Jun Kim from Seoul National University and Ewha Womans University, South Korea, examines a type of cell found in the tissue surrounding tumors, called cancer-associated fibroblasts (CAFs), and asks whether they can predict how a sarcoma patient will respond to immunotherapy. What […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch